Feature

Point-Counterpoint: Should We Implement Needle Exchange Programs for the Prevention of Hepatitis C Virus?

Of the approximately 12.7 to 16 million people who inject drugs (PWID) worldwide, an estimated 10 million individuals have hepatitis C virus (HCV), making it ...

Can Direct-Acting Antivirals Finally Achieve Hepatitis C Elimination?

Unrestricted use of DAAs may be an invaluable component of preventing HCV transmission by reducing the infectious pool of individuals.

Etiology of Acute Liver Failure Can Yield Surprising Findings

Before the advent of potent antiviral agents, liver transplantation was the only treatment option for patients with hepatitis and a poor prognosis; antiretrovirals can now ...

Addressing Palliative Care in Hepatocellular Carcinoma

Research shows that palliative care can help with symptom management, care coordination, therapeutic decision making, and the psychosocial aspects of living with hepatocellular carcinoma.

Biologic Psoriasis Therapies Pose Limited Risk for Hepatitis B Reactivation

In patients with psoriasis who were previously exposed to HBV or who have chronic HBV, immunosuppressive therapies can cause viral reactivation, although the risk is ...

Patients With Rheumatic Diseases Need to Be Monitored for HBV Reactivation

Clinicians need to monitor reactivation of the hepatitis B virus in patients with rheumatic diseases by testing for elevation of liver enzymes and HBV DNA ...

Transfusion-Transmitted Hepatitis B Virus: Minimizing the Risk

The risk for HBV transfusion-transmitted infection has been significantly reduced in the last few decades by the careful selection of donors and testing of blood ...

Closing the Gap in Managing Viral Hepatitis Infections in Refugees and Immigrants

To meet the goals of the World Health Organization for reducing new infections and decreasing deaths associated with hepatitis B and C virus by 2030, ...

News Articles

Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C

Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C

HCV viral eradication resulted in improved left ventricular diastolic dysfunction.

High HCV Sustained Virologic Response Rates With Elbasvir/Grazoprevir in Real-World Setting

High HCV Sustained Virologic Response Rates With Elbasvir/Grazoprevir in Real-World Setting

Real-world effectiveness of elbasvir/grazoprevir for HCV GT1 or GT4 is similar in the US Veterans Affairs-treated population as compared with those reported in clinical trials.

Sofosbuvir/Velpatasvir/Voxilaprevir Improves Outcomes After Prior DAA Regimen Failure

Sofosbuvir/Velpatasvir/Voxilaprevir Improves Outcomes After Prior DAA Regimen Failure

Treatment with sofosbuvir/velpatasvir/voxilaprevir led to improvements in patient-reported outcomes in patients who had previously not responded to another DAA regimen.

Point-Counterpoint: Should We Implement Needle Exchange Programs for the Prevention of Hepatitis C Virus?

Point-Counterpoint: Should We Implement Needle Exchange Programs for the Prevention of Hepatitis C Virus?

Of the approximately 12.7 to 16 million people who inject drugs (PWID) worldwide, an estimated 10 million individuals have hepatitis C virus (HCV), making it the most prevalent infectious disease in this population.

Journal Articles

Sign Up for Free e-newsletters